What Comes After Tirzepatide? EloraTZP, Retatrutide and the Next Generation of Weight-Loss Drugs

Tirzepatide may not be the end of the weight-loss drug revolution. By late 2026, the next generation is already taking shape: retatrutide is pushing average weight loss toward 30%, EloraTZP has beaten tirzepatide alone in a Phase 2 diabetes trial, amylin-based drugs are moving into Phase 3, and oral GLP-1 treatments are making injections less central to the category.

The most interesting change is that drug developers are no longer asking only, "Can we suppress appetite more?" They are combining different metabolic signals to chase greater weight loss, better blood sugar control, better body composition, fewer injections, and potentially more individualized treatment.

Related: tirzepatide vs retatrutide and tirzepatide vs semaglutide.

Wondering whether tirzepatide itself comes as a tablet? See is there a tirzepatide pill.

Only a few years ago, tirzepatide itself looked like the next-generation drug.

Its combination of GIP and GLP-1 receptor activity helped push medication-induced weight loss far beyond what earlier obesity drugs had typically achieved.

Now researchers are using that success as a base layer: add amylin, add glucagon, redesign delivery, or combine weight loss with muscle-preserving biology.

EloraTZP is not a completely new single molecule. It is an investigational combination of tirzepatide with eloralintide, a selective amylin receptor agonist.

Tirzepatide already targets GIP and GLP-1. Eloralintide adds an amylin pathway involved in satiety and calorie intake. Together, the combination is designed to activate three complementary nutrient-responsive hormonal systems.

In September 2026, Lilly reported results from a 48-week Phase 2b study involving 367 adults with obesity or overweight and type 2 diabetes.

The highest studied EloraTZP combination — eloralintide 9 mg plus tirzepatide 15 mg — produced an average 23.3% reduction in body weight.

The tirzepatide 15 mg arm lost 14.8% over the same 48 weeks.

That is an 8.5-percentage-point difference in a population with type 2 diabetes — a group that often loses less weight on incretin-based therapy than people without diabetes.

The highest-dose combination also reduced A1C by an average of 2.9 percentage points, compared with 2.4 points for tirzepatide 15 mg alone.

That is important because next-generation obesity medications are increasingly being judged not only by kilograms lost, but by what they do to the wider metabolic disease that often travels with obesity.

More weight loss did not come free.

Gastrointestinal adverse events were more frequent in the combination groups than with either eloralintide or tirzepatide alone. Most were described as mild or moderate and occurred mainly during dose escalation.

Discontinuation because of adverse events ranged from 10.8% to 27.0% across the EloraTZP combination groups, compared with 2.9% in the tirzepatide-alone arm.

That may become one of the defining questions of the next obesity-drug era: how much extra efficacy is worth how much extra tolerability burden?

In the Phase 2 study, eloralintide and tirzepatide were given as separate injections.

Lilly says the next step is a co-formulated EloraTZP product entering Phase 3 with an optimized dose-escalation schedule.

That detail matters. If slower or redesigned titration can preserve the weight-loss advantage while reducing discontinuations, the Phase 3 version of EloraTZP may look meaningfully different from the Phase 2 experiment.

Eloralintide itself is a major part of the story.

In a Phase 2 study of adults with obesity or overweight without type 2 diabetes, once-weekly eloralintide produced mean weight reductions ranging from 9.5% to 20.1% at 48 weeks, depending on the dose strategy.

That was strong enough for Lilly to move eloralintide into Phase 3 as a standalone obesity treatment as well as continue developing it in combination with tirzepatide.

Retatrutide is another way of asking what comes after tirzepatide.

Instead of combining tirzepatide with a second drug, retatrutide is a single molecule designed to activate three receptors: GIP, GLP-1, and glucagon.

That extra glucagon activity is intended to add another metabolic lever beyond the dual GIP/GLP-1 mechanism of tirzepatide.

In the Phase 3 TRIUMPH-1 obesity trial, the 12 mg retatrutide group lost an average of 28.3% of starting body weight over 80 weeks.

Among participants with a baseline BMI of at least 35 who entered an extension, average weight loss reached 30.3% at 104 weeks.

That is currently one of the clearest signals that medication-induced weight loss may be moving into a range once associated much more strongly with metabolic surgery.

The two programs should not be treated as if they are at the same stage.

Retatrutide has already produced multiple positive Phase 3 trials. Lilly has said it plans to submit the drug to the FDA for obesity in the first quarter of 2027.

EloraTZP, by contrast, is only now moving from Phase 2 into Phase 3.

It is tempting to line up 23.3% for EloraTZP and 28.3% for retatrutide and declare a winner.

That would be misleading.

The EloraTZP result came from 48 weeks in adults with type 2 diabetes. The 28.3% retatrutide result came from 80 weeks in adults without diabetes. Those are very different trial populations and treatment durations.

EloraTZP's most interesting feature is not that its current number is higher or lower than retatrutide. It is that adding amylin produced substantially more weight loss than tirzepatide alone within the same randomized trial.

The pipeline is starting to reveal two major strategies beyond classic GLP-1 treatment.

Both approaches attempt to recruit more of the body's metabolic signaling network rather than pushing one receptor harder and harder.

Lilly is not alone in betting that amylin will matter.

Novo Nordisk is developing zenagamtide, previously known as amycretin, a single molecule that activates both GLP-1 and amylin receptors.

In a Phase 2 study in adults with type 2 diabetes, subcutaneous zenagamtide produced up to roughly 14.5% to 14.6% weight loss at 36 weeks, and the program is advancing into Phase 3.

That does not yet rival the headline retatrutide numbers, but it reinforces a broader trend: amylin has moved from a niche concept into one of the central targets of the next obesity-drug cycle.

The most powerful drug is not automatically the most useful drug.

Future obesity treatments are increasingly being judged on a much bigger scorecard.

Not every next-generation drug needs to beat tirzepatide on percentage weight loss.

Orforglipron, marketed in the U.S. as Foundayo in 2026, represents another direction: a once-daily small-molecule oral GLP-1 that can be taken without food or water timing restrictions.

Its weight-loss percentages are generally lower than the most powerful injectable multi-agonists, but convenience can be its own form of disruption.

A pill that is easier to manufacture, distribute, store, and take could reach people who would never choose or obtain a weekly injectable.

By 2026, the market is beginning to move beyond the scale.

Large weight losses can include lean tissue as well as fat. That has created an entirely new research race around preserving muscle while obesity drugs remove fat.

Experimental myostatin-targeting therapies are already being combined with incretin drugs to test whether future treatment can deliver similar scale loss with better lean-mass preservation.

Obesity treatment may eventually start looking more like hypertension or cancer treatment: different pathways used in different combinations for different patients.

One person may need the strongest possible weight reduction. Another may prioritize tolerability. Another may have type 2 diabetes. Another may be older and need aggressive muscle preservation. Another may strongly prefer a pill.

The next generation may therefore be less about finding one drug that replaces everything and more about building a larger menu of metabolic tools.

We do not know.

The current EloraTZP and retatrutide results come from different populations, different trial phases, and different treatment durations. There is no randomized EloraTZP-versus-retatrutide trial.

What EloraTZP has already shown is arguably more important: tirzepatide's effect can apparently be pushed materially further by adding another hormonal pathway.

No.

A drug does not become clinically irrelevant every time a newer trial produces a bigger percentage.

Tirzepatide is approved, widely used, effective, and supported by mature safety and outcome data. A next-generation therapy would need to show that its extra benefit is worth any extra side effects, complexity, cost, and uncertainty.

The future is more likely to expand the treatment ladder than erase its current rungs.

Retatrutide could move from an investigational drug toward regulatory approval. EloraTZP Phase 3 trials should begin generating a much clearer picture of whether its striking Phase 2 advantage survives in larger studies.

Amylin-based competitors will mature, oral drugs will compete on convenience, and muscle-preserving combinations will test whether future obesity treatment can improve body composition rather than simply produce a smaller number on the scale.

That makes 2027 less likely to be the year of one new miracle drug and more likely to be the year obesity pharmacology starts fragmenting into distinct treatment strategies.

Tirzepatide changed expectations for what a weight-loss medication could do. The drugs coming after it are now changing expectations again.

Retatrutide is pushing average weight loss toward 30%. EloraTZP has shown that adding an amylin agonist to tirzepatide can produce substantially greater weight loss than tirzepatide alone. Zenagamtide and other amylin programs are expanding the same idea, while oral drugs and muscle-preserving combinations are competing on dimensions other than raw efficacy.

The next question in obesity medicine may no longer be simply, "What replaces tirzepatide?" It may be, "Which combination of mechanisms is best for this particular person?"

This article is based on late-2026 clinical development updates and trial results for tirzepatide, EloraTZP, eloralintide, retatrutide, and other next-generation metabolic therapies:

Most of the medicines discussed on this page remain investigational, and development programs, regulatory timelines, doses, and final safety profiles can change. Cross-trial weight-loss percentages should not be treated as direct comparisons unless drugs were tested against each other in the same randomized study. Written for general education; this page is not medical advice. Tirzepatide.review is independent and is not affiliated with, sponsored by, or endorsed by Eli Lilly, Novo Nordisk, or their products.